BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27642386)

  • 1. [Incidence of strokes in HIV-positive patients treated with long term antiretroviral treatment].
    Mapoure YN; Nkongni IN; Luma HN; Ngahane BH; Barla E; Ngwane S; Mouelle AS; Njamnshi AK
    Pan Afr Med J; 2016; 24():45. PubMed ID: 27642386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.
    Laurent C; Kouanfack C; Laborde-Balen G; Aghokeng AF; Mbougua JB; Boyer S; Carrieri MP; Mben JM; Dontsop M; Kazé S; Molinari N; Bourgeois A; Mpoudi-Ngolé E; Spire B; Koulla-Shiro S; Delaporte E;
    Lancet Infect Dis; 2011 Nov; 11(11):825-33. PubMed ID: 21831714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A decade of antiretroviral therapy: a profile of patients with 10 years of highly effective triple therapy].
    Wilson G; Wolff M
    Rev Chilena Infectol; 2012 Jun; 29(3):337-43. PubMed ID: 23096476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of cancer in people living with HIV and prognostic value of current CD4
    Ebogo-Belobo JT; Kagoué Simeni LA; Mbassa Nnouma G; Lawan Loubou M; Abamé I; Tchuisseu Hapi A; Dooh Ngalle S; Hemerode Mbock S; Mpondi Ngole Etame M; Atenguena Okobalemba E
    Bull Cancer; 2019 Mar; 106(3):201-205. PubMed ID: 30502923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.
    Monteiro P; Perez I; Pich J; Gatell JM; Martínez E
    J Antimicrob Chemother; 2013 Feb; 68(2):404-8. PubMed ID: 23109185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era.
    D'Ascenzo F; Quadri G; Cerrato E; Calcagno A; Omedè P; Grosso Marra W; Abbate A; Bonora S; Biondi Zoccai G; Moretti C; Gaita F
    J Cardiovasc Med (Hagerstown); 2015 Dec; 16(12):839-43. PubMed ID: 24979113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia.
    Mann M; Mengistu A; Gaeseb J; Sagwa E; Mazibuko G; Baeten JM; Babigumira JB; Garrison LP; Stergachis A
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1052-60. PubMed ID: 27134056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assessment of option B implementation for the prevention of mother to child transmission in Dschang, Cameroon: results from the DREAM (Drug Resource Enhancement against AIDS and Malnutrition) cohort.
    Altan AM; Taafo F; Fopa F; Buonomo E; Marazzi MC; Nielsen-Saines K; Orlando S; Scarcella P; Ciccacci F; Mancinelli S; Lio MM; Palombi L
    Pan Afr Med J; 2016; 23():72. PubMed ID: 27217896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal trends in antiretroviral use in a cohort of men and women in Ontario, Canada.
    Furler MD; Einarson TR; Walmsley S; Millson M; Bendayan R
    AIDS Patient Care STDS; 2006 Apr; 20(4):245-57. PubMed ID: 16623623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of first-line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study.
    Angriman F; Belloso WH; Sierra-Madero J; Sánchez J; Moreira RI; Kovalevski LO; Orellana LC; Cardoso SW; Crabtree-Ramirez B; La Rosa A; Losso MH
    Int J STD AIDS; 2016 Feb; 27(2):118-26. PubMed ID: 25740759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
    Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
    Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
    Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O;
    AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience.
    Rajasekaran S; Jeyaseelan L; Vijila S; Gomathi C; Raja K
    AIDS; 2007 Jul; 21 Suppl 4():S47-53. PubMed ID: 17620752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in CD4 cell counts between 2 and 3.5 years after initiation of antiretroviral therapy and determinants of CD4 progression in India.
    Rajasekaran S; Jeyaseelan L; Raja K; Vijila S; Krithigaipriya KA; Kuralmozhi R
    J Postgrad Med; 2009; 55(4):261-6. PubMed ID: 20083872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of tuberculosis and early mortality in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary hospital in Addis Ababa, Ethiopia.
    Kassa A; Teka A; Shewaamare A; Jerene D
    Trans R Soc Trop Med Hyg; 2012 Jun; 106(6):363-70. PubMed ID: 22521216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.